Compare AGNC & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGNC | RGEN |
|---|---|---|
| Founded | 2008 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 8.2B |
| IPO Year | 2008 | N/A |
| Metric | AGNC | RGEN |
|---|---|---|
| Price | $10.34 | $156.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | $10.16 | ★ $170.90 |
| AVG Volume (30 Days) | ★ 20.4M | 696.6K |
| Earning Date | 01-26-2026 | 10-28-2025 |
| Dividend Yield | ★ 13.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | 0.03 |
| Revenue | ★ $956,000,000.00 | $707,890,000.00 |
| Revenue This Year | $8.02 | $17.84 |
| Revenue Next Year | $65.46 | $12.57 |
| P/E Ratio | ★ $14.67 | $6,185.26 |
| Revenue Growth | N/A | ★ 11.74 |
| 52 Week Low | $7.85 | $102.97 |
| 52 Week High | $10.67 | $182.52 |
| Indicator | AGNC | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 47.50 |
| Support Level | $10.28 | $160.11 |
| Resistance Level | $10.67 | $165.02 |
| Average True Range (ATR) | 0.15 | 4.97 |
| MACD | -0.02 | -1.27 |
| Stochastic Oscillator | 19.32 | 7.12 |
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.